calcium
pump
sarcoplasm
reticulum
calcium
atpas
play
central
role
cardiac
contract
show
decreas
express
heart
failur
hf
increas
express
hf
model
improv
cardiac
function
use
direct
cardiac
deliveri
adenoassoci
viru
encod
human
hf
normal
canin
model
studi
safeti
efficaci
effect
immunosuppress
tachycardicpac
dog
receiv
left
ventricl
lv
wall
inject
solvent
pace
continu
postinject
week
euthanasia
tissueserum
sampl
analyz
express
western
blot
immun
respons
histolog
antibodi
nonpac
dog
receiv
analyz
week
parallel
cohort
receiv
immunosuppress
aavmedi
cardiac
express
peak
week
declin
p
vs
week
lv
end
diastol
end
systol
diamet
decreas
dog
treat
p
wherea
lv
diamet
increas
control
dog
dog
receiv
develop
neutral
antibodi
titer
cardiac
cellular
infiltr
immunosuppress
dramat
reduc
immun
respons
reduc
inflamm
neutral
antibodi
titer
maintain
express
thu
cardiac
inject
promot
local
express
improv
cardiac
function
howev
protein
level
reduc
host
immun
respons
immunosuppress
allevi
immun
respons
sustain
transgen
express
may
import
adjuv
clinic
gene
therapi
trial
h
eart
failur
afflict
almost
million
peopl
unit
state
american
heart
associ
new
case
heart
failur
diagnos
year
death
attribut
diseas
advanc
pharmacolog
treatment
includ
bblocker
angiotensinconvert
enzym
inhibitor
angiotensin
receptor
blocker
aldosteron
antagonist
decreas
hospit
improv
surviv
patient
mild
moder
symptom
heart
failur
hunt
et
al
addit
devic
therapi
use
implant
cardioverterdefibril
biventricular
pacemak
decreas
sudden
death
improv
pump
function
young
et
al
ventricular
assist
devic
avail
destin
therapi
nguyen
thourani
heart
failur
often
progress
howev
mani
patient
eventu
develop
unremit
endstag
symptom
definit
therapi
avail
patient
cardiac
transplant
unfortun
limit
donor
suppli
elig
releg
therapi
minor
patient
popul
age
incid
heart
failur
rise
need
novel
therapeut
clear
gene
deliveri
use
viral
vector
one
potenti
therapeut
option
adenoassoci
viru
aav
recogn
promis
vector
gene
therapi
applic
nonpathogen
replic
defect
abl
infect
nondivid
cell
includ
cardiomyocyt
capabl
longterm
transgen
express
kaplitt
et
al
xiao
et
al
sarcoplasm
reticulum
calcium
atpas
load
calcium
sarcoplasm
reticulum
implic
regul
progress
dilat
cardiomyopathi
gianni
et
al
cardiac
tissu
isol
patient
anim
heart
failur
messeng
rna
protein
activ
level
declin
ber
et
al
braz
et
al
del
mont
et
al
restor
level
use
adenovir
vector
adenoassoci
viral
aav
vector
shown
improv
function
metabol
andor
surviv
small
larg
anim
model
heart
failur
hajjar
et
al
del
mont
et
al
kawas
et
al
phase
clinic
trial
cupid
celladon
la
jolla
ca
test
safeti
efficaci
catheterbas
cardiac
deliveri
mydicar
patient
advanc
heart
failur
met
primari
safeti
end
point
suggest
efficaci
note
potenti
subject
exclud
preexist
neutral
antibodi
hajjar
et
al
jaski
et
al
jessup
et
al
number
studi
anim
model
mostli
rodent
confirm
aav
promot
longterm
target
gene
express
daya
bern
howev
studi
clinic
trial
larg
anim
model
includ
studi
deliv
baboon
heart
mctiernan
et
al
reveal
rang
inflammatori
immun
respons
aav
vector
transgen
product
may
reduc
transgen
express
herzog
et
al
herzog
et
al
wang
et
al
wang
et
al
jiang
et
al
manno
et
al
mingozzi
high
rais
risk
associ
aavbas
gene
deliveri
procedur
identif
effect
immunosuppress
regimen
aav
gene
deliveri
could
potenti
enhanc
efficaci
improv
safeti
aavmedi
therapi
exampl
report
immunosuppress
limit
develop
antibodi
direct
aavencod
factor
ix
herzog
et
al
herzog
et
al
permit
sustain
aavmedi
minidystrophin
express
dog
skelet
muscl
herzog
et
al
herzog
et
al
wang
et
al
develop
potenti
therapi
heart
failur
studi
trial
use
canin
model
tachycard
pacinginduc
heart
failur
perform
test
safeti
efficaci
deliv
direct
inject
heart
larg
anim
heart
failur
subsequ
clinic
trial
propos
gene
therapi
deliveri
occur
time
ventricular
assist
devic
vad
placement
patient
endstag
heart
failur
observ
direct
cardiac
inject
dog
heart
promot
local
robust
express
reduc
host
immun
respons
howev
limit
immunosuppress
therapi
blunt
immun
respons
allow
persist
longterm
transgen
express
expand
method
section
avail
onlin
supplement
canin
heart
failur
immunosuppress
model
pacemak
implant
right
ventricl
dog
dog
pace
establish
left
ventricular
lv
dysfunct
lv
eject
fraction
administ
direct
inject
epicardi
surfac
left
ventricl
immunosuppress
achiev
nonpac
dog
prednison
cyclosporin
given
twice
daili
begin
week
solvent
inject
studi
review
approv
univers
pittsburgh
pittsburgh
pa
institut
anim
care
use
committe
institut
biosafeti
committe
left
ventricular
dimens
ie
left
ventricular
enddiastol
dimens
lvedd
left
ventricular
endsystol
dimens
lvesd
function
percentag
fraction
chang
fac
assess
twodimension
mmode
echocardiographi
pace
initi
prepac
week
pace
vector
administr
baselin
week
everi
week
vector
solvent
inject
pace
heart
failur
dog
receiv
solvent
monitor
week
n
aav
n
solvent
week
n
aav
n
solvent
euthanasia
antibodi
specif
human
prepar
immun
rabbit
human
peptid
pmtsgvkqkim
amino
acid
residu
ncbi
refer
sequenc
antibodi
crossreact
canin
remov
chromatographi
serum
affin
gel
coupl
peptid
encod
canin
amino
acid
residu
pmtpgvkqkvm
canin
genbank
access
vitro
cellular
respons
peptid
splenocyt
peripher
blood
mononuclear
cell
obtain
dog
receiv
salin
n
n
cell
cultur
pool
contain
peptid
encompass
amino
acid
residu
differ
canin
human
see
supplementari
fig
peptid
sequenc
posit
control
well
contain
pha
phytohemagglutinin
form
gibcolif
technolog
grand
island
ny
neg
control
well
contain
medium
condit
assay
triplic
day
medium
assay
interferon
ifn
c
product
elisa
r
system
minneapoli
mn
accord
manufactur
instruct
data
present
mean
mean
sd
signific
determin
twotail
test
pair
unpair
variabl
analysi
varianc
use
continu
variabl
valu
p
consid
signific
plan
clinic
trial
consid
deliveri
patient
receiv
ventricular
assist
devic
endstag
heart
failur
preclin
studi
two
relat
investig
undertaken
first
canin
model
tachycardiapac
induc
chronic
heart
failur
use
assess
shortterm
safeti
efficaci
cardiacinject
davidoff
gwathmey
nikolaidi
et
al
experiment
design
present
fig
dog
n
studi
end
point
first
receiv
prepac
cardiac
function
assess
underw
percutan
pacemak
placement
induct
heart
failur
administ
two
cm
grid
posit
beat
heart
nine
site
within
grid
inject
ml
either
n
solvent
control
n
dog
inject
one
grid
receiv
low
dose
viral
genomesml
receiv
high
dose
viral
genomesml
pace
reiniti
day
surgeri
maintain
heart
failur
second
arm
sought
assess
longterm
human
express
deliveri
effect
immunosuppress
wang
et
al
longer
time
point
week
dog
n
without
pace
use
avoid
increas
morbid
risk
mortal
anticip
extend
tachycard
pace
dog
place
cardiopulmonari
bypass
without
circulatori
arrest
n
solvent
n
deliv
describ
previous
approxim
half
dog
immunosuppress
begin
week
vector
inject
continu
time
euthanasia
simul
clinic
scenario
vadsupport
patient
receiv
propos
aavbas
gene
deliveri
proceed
cardiac
transplant
subsequ
immunosuppress
stock
produc
tripl
plasmid
transfect
method
xiao
et
al
use
vector
two
sourc
initi
studi
perform
vector
produc
laboratori
purifi
via
heparin
chromatographi
three
four
dog
per
group
addit
studi
perform
good
laboratori
practic
glp
grade
vector
prepar
univers
north
carolina
chapel
hill
nc
joint
vector
laboratori
purifi
ultracentrifug
cscl
gradient
two
dog
per
group
vector
purifi
heparin
chromatographi
time
empti
viral
particl
vector
purifi
ultracentrifug
cscl
gradient
see
onlin
supplement
highli
conserv
protein
among
mammal
campbel
et
al
rabbit
antiserum
produc
differenti
human
canin
protein
fig
lane
h
vs
see
also
supplementari
fig
supplementari
data
avail
onlin
wwwliebert
onlinecomhum
cardiac
extract
highdos
inject
noninject
site
subject
western
blot
analys
reveal
increas
human
express
dog
heart
week
receiv
n
detect
control
dog
receiv
solvent
fig
express
lower
lowdos
inject
site
data
shown
observ
lowlevel
express
noninject
region
cm
inject
site
three
dog
data
shown
result
present
focu
highdos
solventinject
site
quantit
western
blot
dog
cardiac
tissu
fig
show
human
express
variabl
significantli
lower
n
compar
week
p
week
vector
administr
compar
week
similar
reduc
level
found
analyz
week
vector
deliveri
nonpac
dog
heart
n
compar
week
p
hypothes
immunemedi
process
led
decreas
express
immunosuppress
would
preserv
express
test
hypothesi
group
nonpac
dog
receiv
n
solvent
n
immunosuppress
commenc
week
viral
deliveri
continu
zhu
et
al
week
anim
kill
week
postinject
fig
quantit
western
blot
analys
reveal
significantli
p
higher
express
dog
receiv
immunosuppress
compar
anim
immunosuppress
fig
b
data
shown
fig
normal
express
dehydrogenas
gapdh
load
control
normal
base
signal
coomassi
blue
stain
filter
produc
similar
trend
data
shown
dog
n
total
normal
prepac
lv
dimens
function
mean
sd
lvesd
cm
lvedd
cm
fac
develop
increas
lv
systol
dimens
lvesd
cm
p
increas
lv
diastol
dimens
lvedd
cm
p
decreas
percentag
fraction
area
chang
fac
p
baselin
week
pace
vector
deliveri
week
tabl
lvesd
lvedd
significantli
decreas
toward
baselin
level
dog
week
deliveri
week
lvesd
cm
lvedd
cm
p
compar
week
fac
trend
improv
week
reach
statist
signific
six
dog
group
week
p
contrast
solventtr
dog
show
ongo
rel
week
cardiac
dilat
persist
reduc
fraction
shorten
week
lvesd
cm
lvedd
cm
fac
p
signific
solvent
treatment
data
repres
mean
two
dog
vector
distribut
quantif
perform
subset
dog
receiv
glpgrade
assess
potenti
system
vector
deliveri
aris
intracardiac
inject
vector
genom
dna
detect
copi
singlestrand
dna
per
microgram
genom
dna
highdos
lowdos
inject
site
eight
vectortr
dog
fig
gener
lowdos
region
fig
human
express
dog
heart
western
blot
cardiac
extract
highdos
site
analyz
rabbit
antiserum
antigapdh
human
heart
h
solventinject
dog
heart
c
extract
serv
posit
neg
control
respect
western
blot
imag
tachycardicpac
dog
receiv
lane
solvent
tachycardicpac
dog
receiv
lane
solvent
nonpac
dog
receiv
lane
solvent
nonpac
dog
receiv
immunosuppress
lane
solvent
immunosuppress
b
quantit
comparison
express
digit
xray
film
normal
refer
dog
solid
column
dog
plu
n
dark
gray
column
dog
plu
n
light
gray
column
normal
dog
plu
n
open
column
normal
dog
immunosuppress
plu
n
receiv
immunosuppress
w
week
lower
vector
genom
copi
number
rel
highdos
region
among
highdos
region
obviou
differ
dna
copi
number
observ
week
inject
although
region
receiv
lowdos
vector
tend
show
reduct
aav
copi
number
week
inject
immunosuppress
obviou
effect
aav
copi
number
either
lowor
highdos
site
vector
genom
dna
found
low
level
aav
genom
per
microgram
genom
dna
noninject
area
heart
two
vectortr
dog
vector
dna
also
detect
kidney
liver
spleen
sampl
three
individu
dog
leukocyt
posit
vector
within
hr
inject
three
eight
dog
viral
tabl
fac
percentag
fraction
chang
lvedd
left
ventricular
enddiastol
dimens
lvesd
left
ventricular
endsystol
dimens
statist
analys
perform
control
group
n
n
number
dog
echocardiograph
data
avail
two
prepac
data
point
one
data
point
avail
technic
reason
genom
undetect
time
point
blood
sampl
neutral
antibodi
nab
titer
determin
test
abil
serum
antibodi
inhibit
transduct
report
viru
cell
describ
earlier
mctiernan
et
al
studi
use
vector
purifi
either
chromatographi
cscl
gradient
densiti
centrifug
chromatograph
purifi
viral
stock
typic
contain
time
empti
capsid
protein
glpgrade
stock
purifi
cscl
gradient
dog
detect
nab
titer
aav
neutral
antibodi
aav
inject
baselin
dog
develop
posit
aav
nab
titer
week
vector
administr
fig
b
chromatograph
cscl
gradient
densiti
centrifug
purifi
glpgrade
viral
stock
elicit
similar
nab
titer
heart
failur
model
dog
fig
howev
higher
nab
titer
develop
nonpac
dog
receiv
chromatograph
purifi
viru
rel
anim
receiv
vector
prepar
cscl
gradient
densiti
centrifug
glp
grade
fig
interestingli
immunosuppress
commenc
week
viral
inject
continu
week
reduc
nab
titer
baselin
level
fig
sera
collect
dog
week
viru
deliveri
also
use
western
blot
analysi
human
heart
protein
look
antihuman
antibodi
dog
express
human
detect
antibodi
reactiv
human
heart
protein
expect
size
see
supplementari
fig
histopatholog
assess
perform
hematoxylin
eosin
h
e
stain
section
pace
dog
heart
receiv
solvent
fig
substanti
local
myocardi
infiltr
observ
heart
receiv
week
tendenc
toward
less
infiltr
observ
site
receiv
lowdos
viru
inject
data
shown
infiltr
also
present
dog
without
heart
failur
receiv
less
promin
sampl
dog
receiv
immunosuppress
compar
receiv
viru
immunosuppress
fig
obviou
differ
sever
infiltr
dog
receiv
viru
purifi
heparin
chromatographi
cscl
gradient
glp
grade
sampl
dog
receiv
glpgrade
viru
n
solvent
control
n
analyz
semiquantit
fashion
blind
observ
mean
data
deriv
two
highdos
inject
site
two
dog
given
treatment
group
show
infiltr
chronic
inflamm
promin
dog
receiv
inflamm
fibrosi
persist
week
week
viru
inject
immunosuppress
reduc
inflamm
fibrosi
fig
inflamm
fibrosi
consider
less
evid
site
receiv
lowdos
compar
highdos
site
observ
noninject
site
data
shown
nonpac
dog
surviv
period
week
vector
administr
nab
assay
perform
blood
sampl
collect
vector
administr
weekli
biweekli
interv
vector
administr
serum
dilut
valu
averag
group
cp
chromatograph
purifi
glp
good
laboratori
practicegrad
prepar
purifi
cscl
gradient
densiti
centrifug
n
number
dog
per
group
immunofluoresc
microscopi
dog
heart
recov
week
inject
reveal
signific
infiltr
cell
area
adjac
nearnorm
cardiomyocyt
interspers
appear
remnant
cardiomyocyt
fig
signific
morpholog
chang
organ
except
fibrosi
pleura
lung
sampl
consist
injuri
associ
thoracotomi
increas
hepatocyt
cytoplasm
clear
liver
immunosuppress
dog
suggest
mild
steroid
hepatopathi
common
phenomenon
dog
cellular
infiltr
concomit
express
human
suggest
possibl
immun
cell
respons
epitop
differenti
human
canin
even
though
protein
sequenc
conserv
human
canin
assay
cytotox
cell
respons
cell
express
human
splenocyt
peripher
blood
mononuclear
cell
obtain
control
dog
n
salin
inject
dog
receiv
week
earlier
n
cultur
pool
contain
differ
peptid
encompass
amino
acid
residu
differ
canin
human
supplementari
fig
cultur
medium
level
ifnc
determin
assay
cytotox
cell
activ
rimmelzwaan
et
al
wherea
four
cell
sourc
produc
ifnc
respons
posit
control
pha
none
peptid
pool
elicit
detect
level
ifnc
product
see
supplementari
fig
increas
sarcoplasm
reticulum
calcium
uptak
calcium
transient
kinet
via
target
overexpress
gene
therapymedi
approach
suggest
mean
improv
function
fail
mammalian
heart
del
mont
et
al
hajjar
et
al
kawas
et
al
report
use
vector
encod
human
deliv
direct
cardiac
inject
nonfail
fail
dog
heart
assess
effect
express
cardiac
function
heart
failur
model
persist
express
dog
heart
occurr
immun
respons
effect
immunosuppress
express
immun
respons
major
new
observ
studi
follow
despit
limit
area
inject
overexpress
human
accompani
improv
measur
lv
size
cardiac
function
larg
anim
model
tachycardicpac
induc
heart
failur
cellular
infiltr
like
limit
durat
extent
amount
express
immunosuppress
week
vector
deliveri
limit
cellular
infiltr
antiaav
humor
immun
respons
prolong
highlevel
express
paper
demonstr
express
human
larg
anim
model
heart
failur
subsequ
improv
cardiac
dimens
systol
function
although
aav
pseudotyp
may
show
preferenti
organ
tropism
vari
speci
yue
et
al
gener
reason
high
cardiac
skelet
muscl
express
dog
bish
et
al
approach
includ
antibodybas
detect
method
confirm
overexpress
aavencod
human
oppos
enhanc
express
endogen
canin
result
gener
follow
prior
report
target
overexpress
improv
function
fail
mammalian
heart
cardiac
overexpress
adenovir
vector
rat
aortic
band
model
improv
surviv
cardiac
metabol
del
mont
et
al
addit
longterm
overexpress
vector
volumeoverload
porcin
heart
failur
model
revers
cardiac
dysfunct
kawas
zhu
canin
tachycardicpac
model
believ
close
mimic
mani
aspect
human
nonischem
heart
failur
davidoff
gwathmey
previous
use
larg
anim
model
cardiac
gene
therapi
although
deliveri
method
direct
cardiac
visual
inject
invas
may
envis
clinic
trial
permit
high
transduct
local
identifi
area
subsequ
analys
minim
collater
viral
uptak
organ
could
use
time
cardiac
surgeri
clinic
set
import
observ
cellular
immun
respons
vector
deliveri
cardiac
infiltr
like
limit
express
encod
vector
occur
heart
failur
dog
aav
inject
beat
heart
nonpac
dog
inject
cardiopulmonari
bypass
observ
resembl
prior
studi
baboon
cardiac
infiltr
overt
myocard
observ
accompani
rapid
rise
fall
express
secret
gene
product
tnfriifcigg
direct
cardiac
deliveri
vector
mctiernan
et
al
immun
reaction
could
limit
effect
gene
deliveri
andor
lead
progress
worsen
cardiac
function
sever
grade
fibrosi
chronic
inflamm
describ
materi
method
averag
sever
score
two
high
doseinject
site
within
one
heart
subsequ
averag
two
dog
group
ie
data
n
per
group
fibrosi
control
score
zero
aav
receiv
ctl
control
receiv
solvent
receiv
week
immunosuppress
start
week
inject
w
week
inject
c
immunofluoresc
stain
cardiac
tissu
nonpac
dog
week
receiv
noninject
site
control
dog
site
green
phalloidin
sarcomer
blue
dapi
nuclei
red
scale
bar
indic
viral
capsid
protein
viral
encod
human
could
provid
antigen
elicit
cellular
immun
respons
infiltr
fibrosi
occur
use
either
researchgrad
heparin
chromatographypurifi
vector
contain
substanti
level
empti
capsid
rel
full
particl
contain
aav
dna
clinic
trialgrad
vector
prepar
glp
standard
purifi
cscl
gradient
ultracentrifug
separ
empti
capsid
genomecontain
vector
particl
unexpectedli
detect
increas
nab
titer
viru
inject
higher
dog
receiv
researchgrad
versu
clinicalgrad
prepar
although
specif
assess
gener
cellular
antiaav
respons
observ
prior
studi
dog
receiv
aav
vector
wang
et
al
wang
et
al
b
ohshima
et
al
howev
detect
antihuman
antibodi
dog
receiv
cellular
immun
respons
peptid
contain
humanspecificcanin
diverg
amino
acid
suggest
human
protein
elicit
immun
respons
studi
deliv
aav
vector
larg
anim
striat
muscl
skelet
cardiac
detect
infiltr
respons
deliveri
method
titer
aav
particl
experiment
speci
may
contribut
differ
direct
inject
aav
primat
heart
mctiernan
et
al
dog
skelet
muscl
yuasa
et
al
wang
et
al
wang
et
al
induc
cellular
infiltr
wherea
inflammatori
respons
catheterdeliv
cardiac
aav
infus
notabl
kaplitt
et
al
kawas
et
al
raak
et
al
compar
studi
show
direct
inject
aav
induc
infiltr
canin
skelet
muscl
wherea
limb
perfus
gregorev
et
al
ohshima
et
al
studi
also
observ
vector
particl
dosedepend
immun
respons
herzog
et
al
dog
may
also
present
sever
immun
respons
aav
aavencod
protein
speci
mice
yuasa
et
al
strong
cellular
immun
respons
skelet
muscl
deliveri
aav
note
dog
wang
et
al
b
howev
one
studi
detect
minim
cardiac
fibrosi
mononuclear
cell
infiltr
endomyocardi
inject
aav
construct
canin
heart
bish
et
al
light
interest
note
sever
studi
observ
unexpect
prolong
week
month
persist
cellular
respons
viral
antigen
infect
parvoviru
isa
et
al
vesicular
stomat
viru
turner
et
al
influenza
viru
kim
et
al
studi
suggest
longterm
persist
aavantigen
viral
deliveri
jiang
et
al
stieger
et
al
even
low
level
viral
capsid
antigen
mhc
complex
target
cell
recognit
peptidespecif
cytotox
cell
pien
et
al
thu
larg
bolu
foreign
antigen
ie
aav
capsid
deliv
local
inject
striat
muscl
myocardium
could
gener
depot
prolong
cellular
immun
respons
aav
capsid
retain
inject
site
present
cell
recognit
could
contribut
contrast
result
catheterbas
deliveri
aav
vector
encod
human
myocardium
elicit
detect
cellular
immun
respons
kaplitt
et
al
kawas
et
al
raak
et
al
jaski
et
al
heart
failur
may
alter
immun
respons
aav
deliveri
studi
dog
heart
failur
produc
lower
antiaav
titer
normal
dog
observ
may
parallel
studi
human
heart
failur
produc
lower
viral
titer
influenza
vaccin
compar
healthi
control
subject
vardeni
et
al
assess
differ
cellular
respons
direct
cardiac
inject
aav
function
heart
failur
presenc
absenc
howev
note
patholog
inflamm
score
normal
dog
week
receiv
viru
least
sever
observ
heart
failur
dog
week
viru
deliveri
although
phase
cupid
trial
jaski
et
al
jessup
et
al
report
signific
inflammatori
infiltr
respons
aav
deliveri
also
clear
larg
anim
human
clinic
trial
use
aav
display
therapylimit
immun
respons
clinic
trial
use
hepat
deliveri
portal
vein
infus
express
factor
ix
observ
transient
elev
subsequ
decreas
serum
factor
ix
accompani
increas
eventu
fall
serum
liver
enzym
suggest
cellmedi
destruct
liver
cell
load
aav
antigen
manno
et
al
subsequ
studi
demonstr
presenc
cell
reactiv
aav
capsid
epitop
mingozzi
high
indic
human
hepatocyt
contain
even
extrem
low
level
mhc
class
molecul
load
aav
capsidderiv
peptid
target
cytotox
cell
destruct
pien
et
al
suggest
aav
capsid
epitop
present
mhc
class
molecul
import
pathway
aavinduc
cytotox
cell
respons
antiaav
cell
respons
antibodi
product
progress
diminish
vectorencod
gene
express
occur
intramuscular
inject
patient
encod
lipoprotein
antitrypsin
aat
although
persist
lowlevel
aat
express
observ
month
patient
brantli
et
al
sever
immun
respons
aav
encod
factor
ix
hemophiliac
dog
durat
factor
ix
express
depend
least
part
rout
aav
deliveri
develop
antifactor
ix
antibodi
niemey
et
al
thu
immun
respons
aavbas
vector
remain
signific
issu
maxim
safeti
efficaci
aavbas
gene
deliveri
mingozzi
high
recognit
issu
prior
studi
demonstr
use
transient
andor
longterm
immunosuppress
achiev
longer
durat
higher
level
express
aavencod
transgen
herzog
et
al
herzog
et
al
yuasa
et
al
canin
muscular
dystrophi
model
transient
immunosuppress
use
antithymocyt
globulin
cyclosporin
mycophenol
mofetil
start
aav
deliveri
allow
prolong
aavmedi
microdystrophin
express
month
withdraw
immunosuppress
wang
et
al
without
immunosuppress
aavencod
transgen
express
diminish
soon
intramuscular
inject
cell
respons
wang
et
al
b
current
studi
limit
immunosuppress
use
prednison
cyclosporin
start
week
vector
zhu
et
al
administr
reduc
inflamm
aav
nab
titer
preserv
express
interestingli
substanti
chang
aav
genom
copi
number
regardless
level
express
presenc
immunosuppress
fig
may
reflect
least
partial
previous
observ
shutdown
viral
promot
cytomegaloviru
cmv
promot
virusmedi
gene
deliveri
construct
may
suggest
role
inflammatori
respons
process
ser
et
al
acknowledg
sever
limit
studi
difficulti
maintain
tachycardicpac
dog
week
cardiac
function
immun
respons
heart
failur
anim
limit
period
thu
know
long
improv
cardiac
function
might
maintain
assess
human
express
immun
respons
effect
immunosuppress
longer
interv
viru
deliveri
normal
dog
whether
immunosuppress
heart
failur
dog
would
enhanc
cardiac
function
due
enhanc
express
remain
determin
also
clear
whether
immunolog
chang
associ
heart
failur
may
impact
immun
respons
aav
vector
directli
confirm
cellular
respons
aav
capsid
mechan
cardiac
infiltr
decay
express
howev
prior
studi
document
activ
cytotox
cell
larg
anim
includ
canin
aav
capsidderiv
antigen
high
degre
conserv
human
canin
amino
acid
residu
lessen
likelihood
canin
immun
respons
human
inde
humor
respons
detect
assay
humanspecif
peptid
elicit
detect
cellular
respons
indic
interferonc
product
howev
rule
reactiv
level
detect
cellular
respons
reveal
ifnc
product
summari
observ
longterm
express
vector
improv
cardiac
function
larg
anim
model
heart
failur
accompani
cellular
infiltr
humor
respons
aav
eventu
decreas
express
may
limit
efficaci
rais
safeti
issu
may
implic
human
trial
humor
cellular
infiltr
immun
respons
elicit
viru
blunt
immunosuppress
therapi
associ
prolong
express
immunosuppress
therapi
could
prove
benefici
adjuv
aavbas
intervent
human
heart
failur
